|Videos|December 25, 2019
HER2+ mBC: DESTINY-Breast04 Trial
Author(s)Sponsored Content
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Acupuncture Improves Cognitive Function in Breast Cancer Survivors
2
From Stage 4 to Survivor: Dan’s Pancreatic Cancer Journey
3
Light the Night and Survivorship: The Importance of Remembrance
4
FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer
5
